Thyroid Disease in Chronic Hepatitis C Infection Treated With Combination Interferon-a and Ribavirin: Management Strategies and Future Perspective
Authors:
- Huy A. TranHTHuy A. Tran
- Tracey L. JonesTJTracey L. Jones
- Elizabeth A. IannaEIElizabeth A. Ianna
- Aidan FoyAFAidan Foy
- Glenn E.M. ReevesGRGlenn E.M. Reeves
- 1 March 2013
- journal article
- review article
- Published by Elsevier in Endocrine Practice
- Vol. 19 (2) , 292-300
Abstract
No abstract availableKeywords
This publication has 119 references indexed in Scilit:
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control studyBMC Endocrine Disorders, 2011
- FibroSURE™and FibroScan®in relation to treatment response in chronic hepatitis C virusWorld Journal of Gastroenterology, 2011
- The natural history of interferon-α induced thyroiditis in chronic hepatitis c patients: a long term studyThyroid Research, 2011
- Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶Hepatology, 2010
- Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis CGastroenterology, 2010
- Systematic review: non‐invasive methods of fibrosis analysis in chronic hepatitis CAlimentary Pharmacology & Therapeutics, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patientsJournal of Hepatology, 2004
- What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?Hepatology, 1998